MX2019014201A - Composicion farmaceutica y forma de dosificacion farmaceutica que comprenden (e)-4-(2-(aminometil)-3-fluoroaliloxi)-n-ter-butilbenza mida, proceso para su preparacion, metodos de tratamiento y usos de las mismas. - Google Patents

Composicion farmaceutica y forma de dosificacion farmaceutica que comprenden (e)-4-(2-(aminometil)-3-fluoroaliloxi)-n-ter-butilbenza mida, proceso para su preparacion, metodos de tratamiento y usos de las mismas.

Info

Publication number
MX2019014201A
MX2019014201A MX2019014201A MX2019014201A MX2019014201A MX 2019014201 A MX2019014201 A MX 2019014201A MX 2019014201 A MX2019014201 A MX 2019014201A MX 2019014201 A MX2019014201 A MX 2019014201A MX 2019014201 A MX2019014201 A MX 2019014201A
Authority
MX
Mexico
Prior art keywords
fluoroallyloxy
aminomethyl
butylbenzamide
tert
preparation
Prior art date
Application number
MX2019014201A
Other languages
English (en)
Inventor
Egusa Kenji
Katayama Takuma
Yokoyama Kazutoshi
Alexander Bakker Remko
Hang Victor Chong Ngai
Rippmann Jörg
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2019014201A publication Critical patent/MX2019014201A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a composiciones farmacéuticas que comprenden (E)-4-(2-(aminometil)-3-fluoroaliloxi)-N-ter-butilb enzamida que tienen la siguiente estructura química (ver Fórmula) o una sal farmacéuticamente aceptable de la misma como ingrediente farmacéuticamente activo, en particular a composiciones farmacéuticas que comprenden clorhidrato de (E)-4-(2-(aminometil)-3-fluoroaliloxi)-N-ter-butilbenzamida, a formas de dosificación farmacéuticas, a su preparación, su uso y métodos de tratamiento terapéutico.
MX2019014201A 2017-05-31 2018-05-30 Composicion farmaceutica y forma de dosificacion farmaceutica que comprenden (e)-4-(2-(aminometil)-3-fluoroaliloxi)-n-ter-butilbenza mida, proceso para su preparacion, metodos de tratamiento y usos de las mismas. MX2019014201A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762512896P 2017-05-31 2017-05-31
US201762536002P 2017-07-24 2017-07-24
PCT/EP2018/064135 WO2018219982A1 (en) 2017-05-31 2018-05-30 Pharmaceutical composition and pharmaceutical dosage form comprising (e)-4-(2-(aminomethyl)-3-fluoroallyloxy)-n-tert-butylbenzamide, process for their preparation, methods for treating and uses thereof

Publications (1)

Publication Number Publication Date
MX2019014201A true MX2019014201A (es) 2020-01-23

Family

ID=62555045

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019014201A MX2019014201A (es) 2017-05-31 2018-05-30 Composicion farmaceutica y forma de dosificacion farmaceutica que comprenden (e)-4-(2-(aminometil)-3-fluoroaliloxi)-n-ter-butilbenza mida, proceso para su preparacion, metodos de tratamiento y usos de las mismas.

Country Status (12)

Country Link
US (2) US10603292B2 (es)
EP (1) EP3630084A1 (es)
JP (1) JP2020521795A (es)
KR (1) KR20200013714A (es)
CN (1) CN110662534A (es)
AU (1) AU2018275631A1 (es)
BR (1) BR112019022142A2 (es)
CA (1) CA3060536A1 (es)
CL (1) CL2019003463A1 (es)
MX (1) MX2019014201A (es)
PH (1) PH12019502510A1 (es)
WO (1) WO2018219982A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110585160A (zh) * 2019-09-23 2019-12-20 天津嘉汇捷瑞医药科技有限公司 一种应用到浸膏片的薄膜包衣预混剂及其制备方法
WO2021222308A1 (en) * 2020-04-28 2021-11-04 Metacrine, Inc. Ssao inhibitors for the treatment of disease
CN114680296A (zh) * 2022-04-07 2022-07-01 山东禹王生态食业有限公司 一种大豆分离蛋白素鸡蛋清、制备方法和设备

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU222489B1 (hu) 1990-07-25 2003-07-28 Novartis Ag. Stabilizált gyógyszerkészítmények és eljárás az előállításukra
EP1830886B1 (en) 2004-12-27 2016-04-13 Eisai R&D Management Co., Ltd. Method for stabilizing anti-dementia drug
CN101848713B (zh) * 2007-05-21 2012-04-11 东丽株式会社 含有特定的有机酸的口服制剂以及口服制剂的溶出性和化学稳定性的改善方法
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
US9186411B2 (en) 2008-07-28 2015-11-17 Takeda Pharmaceutical Company Limited Pharmaceutical composition
BR112013019026A2 (pt) 2011-02-01 2016-10-04 Astrazeneca Uk Ltd formulações farmacêuticas incluindo um composto amina
SG10201707020TA (en) 2012-05-02 2017-10-30 Boehringer Ingelheim Int Substituted 3-haloallylamine inhibitors of ssao and uses thereof
CA2910121A1 (en) * 2013-04-25 2014-10-30 Kyorin Pharmaceutical Co., Ltd. A pharmaceutical composition comprising a 1,4-dihydroquinoline carboxylic acid a cellulosic excipient and a salting-out agent
SI3302565T1 (sl) * 2015-06-04 2020-02-28 Pfizer Inc. Trdne farmacevtske oblike palbocikliba
EP3386494A1 (en) * 2015-12-07 2018-10-17 Benevolentai Cambridge Limited Vap-1 inhibitors for treating pain

Also Published As

Publication number Publication date
AU2018275631A1 (en) 2019-10-31
WO2018219982A1 (en) 2018-12-06
JP2020521795A (ja) 2020-07-27
KR20200013714A (ko) 2020-02-07
CA3060536A1 (en) 2018-12-06
US10603292B2 (en) 2020-03-31
US20180344672A1 (en) 2018-12-06
PH12019502510A1 (en) 2020-07-13
EP3630084A1 (en) 2020-04-08
CL2019003463A1 (es) 2020-05-08
CN110662534A (zh) 2020-01-07
BR112019022142A2 (pt) 2020-05-12
US20200188337A1 (en) 2020-06-18

Similar Documents

Publication Publication Date Title
NZ734516A (en) Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n’-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
MX2021004431A (es) Procesos novedosos.
MX2019012884A (es) Terapia de combinacion.
MX2020001403A (es) Nuevos derivados de quinolina.
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
MX2021011563A (es) Derivados de 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmaceuticas que los incluyen.
MX2016010179A (es) Composiciones de donepezilo y métodos para tratar la enfermedad de alzheimer.
MY163235A (en) Pharmaceutical preparation containing pyridylaminoacetic acid compound
PH12019502510A1 (en) Pharmaceutical composition and pharmaceutical dosage form comprising (e)-4-(2-(aminomethyl)-3-fluoroallyloxy)-n-tert-butylbenzamide, process for their preparation, methods for treating and uses thereof
PH12019500328A1 (en) Aza-indazole compounds for use in tendon and/or ligament injuries
MX2022002196A (es) Composición de liberación retardada de niclosamida y uso antiviral de la misma.
MX2021006156A (es) Compuestos utiles en la terapia para el vih.
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
WO2016168553A8 (en) Deuterated obeticholic acid
PH12015501945B1 (en) Formulations of organic compounds
EP4234021A3 (en) Pharmaceutical composition comprising an adenosine derivative for use in the prevention or treatment of diabetic nephropathy
PH12019500327A1 (en) Indazole compounds for use in tendon and/or ligament injuries
PH12017501668A1 (en) Bace1 inhibitors
WO2017168454A3 (en) Novel compounds as btk inhibitors
EA201992816A1 (ru) Фармацевтическая композиция и лекарственная форма, которая включает (e)-4-(2-(аминометил)-3-фтораллилокси)-n-трет-бутилбензамид, способ их приготовления, способы лечения и их применения
JOP20200005A1 (ar) تركيبات صيدلية
MX2018013070A (es) Combinación farmacéutica que comprende clorhidrato de tramadol de liberación extendida y etoricoxib de liberación inmediata, y su uso para el tratamiento del dolor.
EA201792265A1 (ru) Способы лечения сердечно-сосудистых заболеваний
EP3795170C0 (en) PHARMACEUTICAL COMPOSITION COMPRISING CCN5 USED AS AN EFFECTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF RETINAL DISEASE
EA201991008A1 (ru) Новые производные нафтиридинона и их применение в лечении аритмии